A H Walsh - JoVE Visualize

Showing results (1-10 of 5) with videos related to

Pageof 1

Sort By:

Journal of Wildlife Diseases|January 1, 1983

Skeletal lesions and deformities in large sharksJ M Hoenig, A H Walsh

FEBS Letters|December 31, 1997

Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2AA H Walsh, A Cheng, R E Honkanen

Cancer Research|August 29, 1998

Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activityA Cheng, R Balczon, Z Zuo, et al.

The Journal of Pharmacology and Experimental Therapeutics|December 1, 1996

Model development and analysis of tenidap-induced proteinuria in the ratM D Aleo, T Wang, G Giebisch, et al.

Circulation|September 17, 1998

Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemiaC Weinbrenner, C P Baines, G S Liu, et al.

Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:

Pageof 1

Journal of Wildlife Diseases|January 1, 1983

Skeletal lesions and deformities in large sharksJ M Hoenig, A H Walsh

FEBS Letters|December 31, 1997

Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2AA H Walsh, A Cheng, R E Honkanen

Cancer Research|August 29, 1998

Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activityA Cheng, R Balczon, Z Zuo, et al.

The Journal of Pharmacology and Experimental Therapeutics|December 1, 1996

Model development and analysis of tenidap-induced proteinuria in the ratM D Aleo, T Wang, G Giebisch, et al.

Circulation|September 17, 1998

Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemiaC Weinbrenner, C P Baines, G S Liu, et al.

Pageof 1